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Objectives
To externally validate risk models for the detection of kidney cancer, as early detection of kidney cancer improves survival
and stratifying the population using risk models could enable an individually tailored screening programme.
Methods
We validated the performance of 30 existing phenotypic models predicting the risk of kidney cancer in the UK Biobank
cohort (n = 450 687). We compared the discrimination and calibration of models for men, women, and a mixed-sex
cohort. Population level data were used to estimate model performance in a screening scenario for a range of risk
thresholds (6-year risk: 0.1–1.0%).
Results
In all, 10 models had reasonable discrimination (area under the receiver-operating characteristic curve >0.60), although
some had poor calibration. Modelling demonstrated similar performance of the best models over a range of thresholds. The
models showed an improvement in ability to identify cases compared to age- and sex-based screening. All the models
performed less well in women than men.
Conclusions
The present study is the first comprehensive external validation of risk models for kidney cancer. The best-performing
models are better at identifying individuals at high risk of kidney cancer than age and sex alone; however, the benefits are
relatively small. Feasibility studies are required to determine applicability to a screening programme.
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Introduction
Kidney cancer is the seventh most common cancer in Europe
[1], responsible for 50 000 annual deaths [2,3]. Incidence is
projected to rise in coming years, due to changes in
population demographics and lifestyle [1]. Early-stage
diagnosis is strongly correlated with improved survival rates;
The 5-year cancer-specific survival rates for patients
diagnosed with Stage I and IV kidney cancer are 83% and
6%, respectively [4]; in the UK ~25% of patients who present
with kidney cancer have evidence of metastases. In the UK,
60% of kidney cancers are diagnosed incidentally with ~20%
of these being late stage (III–IV) [5]. A lack of symptoms,
even at late stages of the disease, makes the early detection of
kidney cancer particularly challenging.
There are several risk factors that are known to be associated
with kidney cancer and these have been combined to develop
a number of risk models, as identified in a recent systematic
review [6]. It has been suggested that such risk models could
be used to identify high-risk individuals for inclusion in a
screening programme [7], with the development and
validation of risk models being identified as a research
priority in a recent review of screening for kidney cancer [8].
Risk-stratified screening could improve screening efficiency,
while reducing the associated costs and harms compared to a
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simple age-based approach [9,10]; this is crucial when
considering diseases, such as kidney cancer, with a relatively
low prevalence [11]. However, the performance of most of
the published models that predict individual-level risk of
developing kidney cancer have not be externally validated.
Therefore, the potential of these models to assess eligibility is
unclear and comparisons to other approaches (such as using
age- and sex-based selection) is not possible.
In the present study, we externally validated 30 of these
models in the UK Biobank (UKB), a cohort of >500 000
people. We then applied a public health modelling approach
to estimate the population level health benefit of
incorporating the best performing models within a risk-
stratified kidney cancer screening programme. The use of risk
models to determine eligibility for screening was compared to
age- and sex-based strategies.
Methods
Selection of Risk Prediction Models
We identified risk prediction models from our recent
systematic review [6]. We found 60 studies describing model
that predict the risk of an individual developing kidney
cancer. Only models with phenotypic risk factors were
included in this validation. Where there was insufficient detail
about the models, the authors were contacted; these models
were excluded if additional information was not obtained
(n = 8). Models including more than one risk factor for
which there is no comparable UKB variable were excluded
(n = 8). A total of 16 studies (29 models) were included in
this validation study [7,12–27] (Fig. S1). Following discussion
with experts, an additional study published after the
systematic review was included [7]. Details of the
development studies, including study type, population, sample
size and location are given in Table S1.
Validation Cohort
The UKB was used as the validation cohort. It is the largest
population-based cohort in the UK [28]; between the years
2006 and 2010, ~500 000 individuals aged 40–69 years, were
recruited. Demographic and lifestyle information was
recorded at baseline assessment; however, no imaging was
carried out. Details of how risk factors were used is provided
in Table S5. Data on cancer incidence is available through
linkage to national cancer registries (Methods S1).
Members of the cohort with a diagnosis of kidney cancer
prior to baseline were excluded from analysis. If more than
one diagnosis was recorded, the first occurrence was used.
The most recent cancer diagnosis in the dataset is December
2016. We censored all follow-up to 31 March 2016 (the study
end date) to ensure that late registrations were not missed. A
closed cohort analysis was conducted; individuals whose
follow-up was censored before 6 years were excluded. Cases
were those who developed kidney cancer within 6-years of
baseline assessment. This follow-up time is longer than the
estimated sojourn time of RCC (3.7–5.8 years [29,30]).
Model Validation
For all included models, we first computed the score, relative
risk, or absolute risk (depending on model type) for each
eligible UKB participant at baseline. Models predicting the
absolute risk over a specific period were re-scaled to predict
6-year risk (Methods S1). We calculated the performance of
the models both separately for men and women and as a
whole cohort. Models developed originally for single sex
cohorts were not validated for the other sex or the whole
cohort. Where a study developed separate models for men
and women the sex-specific risk predictions were combined
for validation in the whole cohort.
A complete case approach was used for the primary analysis
with each model only computed for individuals with data for
all the risk factors. This was performed on a model-by-model
basis; hence, the cohort size varies slightly for each validation.
The outcome (diagnosis of kidney cancer) was treated as a
binary variable. The discriminative ability of each model was
measured quantitatively using the area under the receiver-
operating characteristic curve (AUROC). The calibration of
the models was assessed graphically using deciles (or
maximum number of possible groups) of predicted risk
(Methods S1). The observed to expected ratio (O:E) and the
Hosmer–Lemeshow statistic were calculated for absolute risk
models.
Sensitivity analyses were carried out. An open cohort analysis
included all participants with <6 years follow-up and cases of
kidney cancer occurring after 6 years. In that analysis, we
used Harrell’s C-statistic to assess discrimination, as it
accounts for censoring. Secondly, we performed a complete-
case analysis using a subset of participants with complete data
available for all models.
Public Health Modelling
Further analyses were carried out to assess the potential
benefits of using these models in the UK general population.
Five models predicting absolute risk, with good performance
in validation (AUROC >0.60, 0.5<O:E<2) were selected for
this analysis [31].
First, we used a re-calibration method (previously described
[32,33]) to re-scale the risk distributions of the models to
reflect the expected risk distribution in the general population
(Methods S1). Second, we developed a set of scenarios using
different risk thresholds (0.1–1.0% 6-year risk) as a cut-off for
screening eligibility. For each model, members of the cohort
with a predicted risk higher than the threshold were classified
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as high-risk and hence ‘eligible’ for screening. Cases of kidney
cancer in the high-risk group are considered identifiable in
that screening scenario.
The proportion of true positives, false positives, false
negatives, and true negatives were calculated for each sex
and 5-year age group. These were then summed with
weighting that reflected the age and sex distribution and the
incidence of kidney cancer in the UK (using Cancer
Research UK [CRUK] and Office for National Statistics
[ONS] data) [34]. Using this new representative population,
the efficacy of the model was determined for each screening
scenario. An overview of this analysis process is given in the
Methods S1.
We assessed accuracy of the models by calculating the
sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) for each threshold. The
efficiency of each screening scenario was assessed by
calculating the proportion of the population invited to
screening, the proportion of people subsequently diagnosed
with kidney cancer within current routine care during the
following 6 years who are invited, and the number of people
needed to invite to identify one individual who is
subsequently diagnosed with kidney cancer within 6 years
(NNI). These screening scenarios were compared to age- and
sex-based risk stratification. Sub-group analyses by sex and
age group were carried out for one threshold (0.4%), selected
pragmatically to represent a potential cut-off that selects
~10% of the population. This modelling approach assesses the
potential of the risk models to determine screening eligibility;
however, the practicalities of screening (such as the
performance of screening tests and attendance at screening)
are not factored into this analysis and the results are not
dependent on screening modality.
Results
A cohort of 450 687 individuals, including 635 cases of
kidney cancer, were included in the primary analysis (Fig. 1).
Compared to those who did not develop kidney cancer, the
cases were more likely to be male, White, overweight, an ever
smoker (and have higher pack-years), hypertensive, and have
a previous cancer diagnosis (Table 1).
The models either assign scores (n = 4) [13,19], calculate a
relative risk (n = 17) [12,14–18,20,22–24,26,35], or calculate
an absolute risk over a defined period (n = 9) [7,21,25,27]
(Table 2, [7,12–27]). The most commonly included risk
factors were body mass index (BMI; n = 29), smoking
(n = 22), hypertension (n = 18), and age (n = 13). Five
studies with mixed sex development populations published
separate models for men and women [12,17,19,23,27]. A total
of 10 models included sex as a distinct risk factor [7,20–
22,25,26]. None of the variables used in the models had
>2.1% missing data in the UKB cohort (Table S5).
Discrimination
Figure 2A–C shows AUROC values for the models validated
in men, women, and the whole cohort. Most of the models
have poor discriminative ability; 0.5<AUROC<0.6. The
Singleton et al. [7], Scelo et al. [25], Usher-Smith et al. [27]
and four of the Landsman and Graubard al. [21] models have
reasonable discrimination in the mixed sex cohort
(0.67<AUROC<0.71), men (0.64<AUROC<0.71) and women
(0.62<AUROC<0.72). Originally developed in women, the
two Sanfilippo et al. [24] models have reasonable
discriminative ability in women (0.61<AUROC<0.70).
These 10 models all include age as a risk factor. Several also
include blood pressure as a risk factor, either a hypertension
diagnosis [7,21] or a direct measurement [7,24]. The results
of the sensitivity analyses were consistent with the primary
analysis (Table S2).
Calibration
The calibration of the models in the UKB cohort is shown
graphically in Fig. S2a–e for men, women, and the whole
cohort. Some of the models show good calibration
(Landsman and Graubard [21] 2013 [b]); however, most
show discrepancies from ideal calibration. Common issues
include overestimation of the risk in the lower deciles
(Scelo et al. [25] 2018), good correlation but poor
calibration (Landsman and Graubard [21] 2013 [d]) and
no clear correlation (Landsman and Graubard [21] 2013
[a]).
Three of the absolute risk models (Singleton et al. [7] 2020,
Landsman and Graubard [21] 2013 [b] and [c]) have non-
significant Hosmer–Lemeshow tests, indicating well calibrated
models (Table S3). In the mixed sex cohort, these three
models have O:E values of 1.1, 1.1, and 1.2. The Scelo et al.
[25] and Usher-Smith et al. [27] models have O:E values of
0.6 and 0.7, showing reasonable calibration.
Public Health Modelling
The adjusted population used in this analysis was scaled to
have 100 000 individuals aged 40–70 years. This population
has the same age and sex distribution (within this age range)
as the UK and the same incidence of kidney cancer. Over a
6-year period, 212 population members (139 men, 72
women) are expected to develop kidney cancer. If a screening
programme included all 100 000 individuals and detected all
cases (over 6-years), 471 individuals would be invited per case
identified (NNI).
The Usher-Smith et al. [27], Scelo et al. [25], Singleton et al.
[7], Landsman and Graubard [21] 2013 (b) and (c) models
were included in this analysis. Table 3 [7,21,25,27] and Fig. 3
compare the performance of the models and other screening
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strategies over the range of risk thresholds (0.1–1.0%). For all
models, as the risk threshold (and the proportion of the
population screened) increases, the sensitivity of the models
increases while the specificity (and NNI) decreases. Very
few individuals were predicted to have a risk >1% for any
model. No meaningful differences are seen between the five
models.
At a risk threshold of 0.4% the NNI is <200 for all five
models. The Landsman and Graubard [21] (b) model detects
the highest number of kidney cancer cases, 32.5% (69/212),
screening 12.7% of the population with a corresponding NNI
of 183. The Scelo et al. [25] model detects the least number
of cases at this threshold, 27.8% (59/212); however, a slightly
lower proportion of the population are screened (11.7%), with
a corresponding NNI of 199. As seen in Fig. 3, the models
performed slightly better than the age- and sex-based
screening strategies. If all men aged ≥60 years in the
modelling population were screened (14.1%), then 29.7% (63/
212) of cases are identified (NNI = 206).
Table S4 compares the model performance at a risk threshold
of 0.4% (a) to the age- and sex-based strategies (b) broken
down by sex and 5-year age group. For all five models, the
subgroup with the oldest men (65–69 years) has the highest
screening rate and the highest detection rate; the two
Landsman and Graubard [21] models have the lowest
NNI (178) in this subgroup.
UKB cohort
n = 502 619
UKB participants
with consent
n = 502 488
UKB participants with
at least 6-years of
follow-up
n = 541 132
UKB participants without
a diagnosis of kidney
cancer
n = 449 871
UKB participants with











n = 51 356
Participants with a
diagnosis of kidney












Fig. 1 Cohort selection process. This flow diagram describes the process used to select a cohort from UKB for the primary analysis in this study.
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Fig. 2 Model discrimination. AUROC value and 95% CIs in (A) whole cohort, (B) men only, and (C) women only. Model type and use of age as a risk
factor are indicated on the figure. Model order is determined by number of risk factors used, from left to right, lowest to highest.
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A lower proportion of cases is detected in women than men
by all of the models at this threshold. The Landsman and
Graubard [21] (b) model correctly identifies the most cases in
women, 11.1% (8/72) compared to 43% (60/139) in men. The
screening strategies based on age only ≥60 years) detect
similar proportions of cases in men and women (25.9% and
26.4%); however, the corresponding NNI is much higher for
women (249 compared to 189 for men). The Landsman and
Graubard [21] and Singleton et al. [7] models classify higher
proportions of younger age groups as high risk than other
models. In the 55–59-year age group, the Landsman and
Graubard [21] (b) model classifies 30.3% of men and 3.9% of
women high risk, identifying 50% (14/28) and 21.4% (three of
14) cases, respectively. In comparison, the Scelo et al. [25]
model classifies 15.5% of men and 0.2% of women in that
group as high risk, accurately identifying 17.9% (5/28) of
cases in men and none in women.
Discussion
We have performed the first comprehensive and systematic
validation of risk models (n = 30) for kidney cancer in the
largest available UK cohort (n = 502 536). In total, 10 models
had adequate to good (0.61<AUROC<0.72) discrimination in
men [7,21,25,27], women [7,21,24,25,27] or the whole cohort
[7,21,25,27]. Measures of sex (n = 20), smoking (n = 22) and
BMI (n = 29) are included in the majority of models. The
highest performing models all included age as a risk factor
and several included hypertension. This is consistent with
current literature about risk factors for kidney cancer
[30,36,37].
The best performing models show discriminative ability
comparable to that for models for colorectal cancer [38],
breast cancer [39] and melanoma [40] in similar studies. The




Proportion of the Population Screened Proportion of Cases Identified
Number of Individuals Invited per case Identified
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Fig. 3 The impact of using the five best performing models in a screening programme is described by (A) the proportion of the population screening,
(B) the proportion of cases detected, (C) the number needed to invite and (D) the summary ROC curve, over a range of cut-off thresholds. The relative
performance screening all individuals aged >60 years and men aged >60 years are indicated on these graphs.
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phenotypic risk factors is limited by the relatively low
population prevalence (0.17, 95% CI 0.09–0.27) in Europe
[11]) and relatively weak risk factor associations (e.g. heavy vs
never smoker, hazard ratio [HR] 1.83, 95% CI 1.26–2.65
[36]). Models may be improved in the future by the addition
of biomarkers or genetic risk factors; however, more research
is required to identify suitable candidates [6].
Given the relatively low prevalence of kidney cancer in the
general population, age-based screening, such as currently
used for colorectal cancer screening in the UK, is unlikely to
be implemented. In the public health modelling, the five risk
models investigated had slightly better performance than the
age- and sex-based strategies in a UK population. The use of
any one of these models to identify individuals at higher risk
of developing kidney cancer could provide a more nuanced
selection process for screening. An ideal screening strategy
would provide an efficient method of detecting early stage
kidney cancer while minimising the number of unaffected
individuals screened. At a threshold of 0.4%, all of the models
have an NNI of <200, screening between 11% and 13% of the
population and detecting between 27% and 33% of cases.
This is comparable to screening all men aged ≥60 years,
where 14.1% of the population are screened and 29.7% of
cases are identified (NNI = 206).
The Landsman and Graubard [21] and Singleton et al. [7]
models additionally performed particularly well in younger
men. At a threshold of 0.4%, the Landsman and Graubard
[21] (b) model identified 38% of cases in men aged 45–
49 years, although only 7% of this subgroup are classified as
high-risk (NNI = 119). Within the context of a screening
programme, these models offer the opportunity to identify
younger individuals likely to benefit from screening while
reducing unnecessary screening amongst low-risk older
individuals.
A further important finding is that at a threshold of 0.4%, all
of the models classified more men than women as high risk.
As a result, using any of the models to determine eligibility
for screening would result in a greater proportion of men
being invited for screening than women. Given the higher
incidence of kidney cancer in men than women (62% of cases
are in men in the UK [41]) this may be a reasonable strategy,
with men, who are on average at higher risk, being screened
and women, who are on average at lower risk, avoiding
screening or being screened at older ages. However, all the
models also identified a smaller proportion of women who
later developed kidney cancer; e.g. the Usher-Smith et al. [27]
model detects 44.8% of men who developed kidney cancer
but only 2.2% of women, although the NNI for men and
women is similar (190 and 192). Using a strategy like this
raises ethical considerations about missing more cases in
certain subgroups of the population, and equitable
distribution of the benefits and harms of screening. Previous
research has shown that selection by a complex risk score is
more acceptable to the public than age and sex alone [42].
Recent cost analysis work around kidney cancer screening
(using ultrasonography screening) estimated the incremental
cost effectiveness ratio to be <£20 000 per quality adjusted
life year for men, but not women (when compared to existing
practice in the UK) [43]. Using a risk model could result in
reduced costs if the population selected screened has a higher
prevalence of kidney cancer. However, compared to age- and
sex-based strategies, use of these risk models to determine
eligibility for screening would require additional data about
individuals, increasing the resources required. The Scelo et al.
[25] and Usher-Smith et al. [27] models require minimal
additional information (BMI and smoking status), often
available in primary care records. However, the Landsman
and Graubard [21] models require information that is not
routinely collected, such as educational level.
Strengths and Weaknesses
To our knowledge, the present study is the first validation of
multiple risk models predicting the development of kidney
cancer. Previously only the models by Usher-Smith et al. [27]
had been externally validated; our present results are similar
to these prior validations [7,27].
A key strength of the present study is the use of the large
UKB cohort. In the primary analysis there were 635 cases
(408 in men and 227 in women), sufficient for a robust
validation [44,45]. Although recruitment for the UKB cohort
was designed to be wide reaching, there is evidence of
selection bias [46]. The participants differ from the general
population in demographics, lifestyle, and health outcomes;
the rates of cancer are 11.8% lower than in the UK
population [46]. This bias is mitigated in our present analysis
by re-scaling predicted risk distributions and standardising
the results to reflect the UK population age and sex
distribution and kidney cancer incidence. This assumes that
cases of kidney cancer in UKB are similar to cases in the UK
population but does not address other differences between
UKB and the general population. Further, we note that
kidney cancer is most common in older individuals (median
age at diagnosis is 65 years) and the UKB cohort only covers
the age range 40–70 years (46–76 years at study end).
Performance of the models in older groups may differ from
the results in the present study. Future validations should
consider these limitations when selecting an appropriate
cohort to test these models.
There is no information in the UKB dataset about histological
subtype or stage of cancer at diagnosis. As sub-types of
kidney cancer are aetiologically different, it is not clear if the
validated models are suitable for predicting the development
of all kidney cancers. Many of the models validated were
© 2021 The Authors.
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originally developed for RCC only (Table S1) and most were
developed in retrospective cohorts (not specifically designed
for screening programmes) [6]. A potential issue with
screening is the over-identification of early stage, low-grade
cancer. Renal imaging was not carried out for the UKB
cohort, so we do not have information about the presence of
kidney cancer at baseline and rely on diagnoses in routine
care to identify cases. However, as many kidney cancers are
currently detected at a late stage (45% Stage III–IV in UK), it
is likely that many cases could be detected earlier if a
screening programme was implemented. Whether this would
translate into a survival benefit is currently unknown and
beyond the scope of the present study.
More generally, it is important to consider that variation in
performance of the models may also reflect differences in
their development populations. Models developed in
populations similar to the UKB cohort are likely to perform
better in this validation. For example, the Singleton et al. [7]
model, developed in a pan-European cohort, has good
discrimination and calibration in the present study. On the
other hand, the Joh et al. [18] models, developed in a USA
cohort, perform relatively poorly.
In the public health modelling analyses, we assumed that all
eligible participants attend screening and that the programme
detects all kidney cancers otherwise diagnosed within 6-years.
Therefore, the estimates of accuracy are overestimates (and
the NNI underestimates) of the real-life implementation of
these scenarios. The potential of these models should be
considered within the context of a best-practice screening
programme and issues including the performance of
screening tests, attendance at screening and existing
diagnostic pathways should be included in any feasibility
studies, as they are in the ongoing Yorkshire Kidney
Screening Trial [47]. However, while underlying population
prevalence and understanding of the speed with which kidney
cancers progress from early to late stage remain uncertain
[11], it is not possible to estimate the actual benefits and
harms of a kidney cancer screening programme. Randomised
controlled trials that compare organised screening to current
practise are required understand the role that screening could
play in improving health outcomes.
Conclusions
The present validation study identified five models with good
discrimination and calibration in a large UK cohort. These
best-performing models are better at identifying individuals
who are later diagnosed with kidney cancer than criteria
based on age and sex alone, and so could potentially improve
the efficiency of a kidney cancer screening programme if used
to determine eligibility. However, the benefits of using any of
the models over age or sex alone remain small. All of the
models additionally struggled to identify women at high risk
of kidney cancer and the number of people needed to invite
to identify one individual who is subsequently diagnosed with
kidney cancer within 6 years was >100 for most thresholds.
Future research is needed to combine these phenotypic
models with other biomarkers, including genetic risk factors,
to improve performance.
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